AU2010228902A1 - Process for the preparation of alogliptin - Google Patents

Process for the preparation of alogliptin Download PDF

Info

Publication number
AU2010228902A1
AU2010228902A1 AU2010228902A AU2010228902A AU2010228902A1 AU 2010228902 A1 AU2010228902 A1 AU 2010228902A1 AU 2010228902 A AU2010228902 A AU 2010228902A AU 2010228902 A AU2010228902 A AU 2010228902A AU 2010228902 A1 AU2010228902 A1 AU 2010228902A1
Authority
AU
Australia
Prior art keywords
compound
formula
vii
represented
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2010228902A
Other languages
English (en)
Inventor
Ehud Marom
Michael Mizhiritskii
Shai Rubnov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mapi Pharma Ltd
Original Assignee
Mapi Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mapi Pharma Ltd filed Critical Mapi Pharma Ltd
Publication of AU2010228902A1 publication Critical patent/AU2010228902A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
    • C07C275/48—Y being a hydrogen or a carbon atom
    • C07C275/50—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2010228902A 2009-03-26 2010-03-25 Process for the preparation of alogliptin Abandoned AU2010228902A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16348109P 2009-03-26 2009-03-26
US61/163,481 2009-03-26
PCT/IL2010/000260 WO2010109468A1 (en) 2009-03-26 2010-03-25 Process for the preparation of alogliptin

Publications (1)

Publication Number Publication Date
AU2010228902A1 true AU2010228902A1 (en) 2011-10-06

Family

ID=42780220

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010228902A Abandoned AU2010228902A1 (en) 2009-03-26 2010-03-25 Process for the preparation of alogliptin

Country Status (9)

Country Link
US (1) US8841447B2 (enExample)
EP (1) EP2410855B1 (enExample)
JP (1) JP2012521411A (enExample)
CN (1) CN102361557A (enExample)
AU (1) AU2010228902A1 (enExample)
BR (1) BRPI1013561A8 (enExample)
CA (1) CA2755561A1 (enExample)
MX (1) MX2011010079A (enExample)
WO (1) WO2010109468A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2673256B1 (en) 2011-02-10 2015-04-08 Solvay SA Process for the manufacture of fluoromethoxymalonic acid derivatives
WO2013046229A1 (en) * 2011-09-26 2013-04-04 Hetero Research Foundation Novel salts of alogliptin
CN102942556A (zh) * 2012-12-04 2013-02-27 成都天翼医药科技有限公司 一种苯甲酸阿格列汀的制备工艺
CN103910710B (zh) * 2012-12-29 2017-06-16 乳源东阳光药业有限公司 阿格列汀新晶型及其制备方法
CN103193762B (zh) * 2013-03-29 2015-07-29 山东罗欣药业集团股份有限公司 苯甲酸阿格列汀的制备方法
US9776985B2 (en) 2013-05-24 2017-10-03 Glenmark Pharmaceuticals Limited Process for preparation of alogliptin
CN104447685A (zh) * 2013-09-23 2015-03-25 上海天慈生物谷生物工程有限公司 一种阿洛利汀的制备方法
WO2015092739A1 (en) * 2013-12-19 2015-06-25 Mylan Laboratories Ltd. Process for preparation of alogliptin
CN105085475B (zh) * 2014-05-09 2019-05-21 上海科胜药物研发有限公司 一种合成阿格列汀中间体的方法
CN104086527B (zh) * 2014-07-03 2016-09-21 湖南欧亚生物有限公司 一种苯甲酸阿格列汀的合成方法
CN105315256B (zh) * 2014-07-07 2018-02-06 广州朗圣药业有限公司 一种适合工业化的高纯度琥珀酸曲格列汀的制备方法
CN105777709A (zh) * 2014-12-22 2016-07-20 上海医药工业研究院 阿格列汀的制备工艺
WO2016178246A1 (en) 2015-05-04 2016-11-10 Indoco Remedies Limited Process for the preparation of alogliptin
CN104961726A (zh) * 2015-06-19 2015-10-07 浙江永宁药业股份有限公司 一种曲格列汀的制备方法
CN105801490B (zh) * 2016-05-05 2019-08-23 傅晓倩 一种制备阿格列汀中间体的方法
CN105837557A (zh) * 2016-05-05 2016-08-10 青岛辰达生物科技有限公司 一种用于治疗ii型糖尿病的阿格列汀的制备方法
CN105968091A (zh) * 2016-05-05 2016-09-28 青岛辰达生物科技有限公司 一种制备治疗ii型糖尿病药物阿格列汀的方法
CN107311940B (zh) * 2017-07-26 2019-08-30 中国人民解放军第三军医大学 一种嘧啶二酮类化合物的制备方法
CN110128401B (zh) * 2018-02-02 2020-04-28 新发药业有限公司 一种苯甲酸阿格列汀的简便制备方法
CN109232443B (zh) * 2018-10-29 2022-03-08 中国药科大学 嘧啶酮衍生物、其制备方法及医药用途
CN114057685A (zh) * 2020-07-31 2022-02-18 西安新通药物研究有限公司 一种高收率苯甲酸阿格列汀的制备方法
CN114105889B (zh) * 2021-12-16 2023-06-13 山东创新药物研发有限公司 一种dpp-iv抑制剂关键中间体的制备方法及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8031A (en) * 1851-04-08 Gkraih separator and ban
US2598936A (en) * 1950-04-13 1952-06-03 Searle & Co Disubstituted cyanoalkanoylureas and thioureas and methods for their production
US4089959A (en) * 1976-03-31 1978-05-16 Cooper Laboratories, Inc. Long-acting xanthine bronchodilators and antiallergy agents
DE4114238A1 (de) * 1991-04-26 1992-10-29 Zentralinstitut Fuer Organisch Neue substituierte 2,2 -pentamethylen-(delta)(pfeil hoch)3(pfeil hoch)-imidazolin-5-one bzw. 2,2 -pentamethylen-imidazolidin-5-one und verfahren zu deren herstellung
TW252044B (enExample) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
JPH08319288A (ja) * 1994-06-20 1996-12-03 Takeda Chem Ind Ltd 縮合イミダゾール誘導体、その製造法及び剤
JPH10508032A (ja) * 1994-12-13 1998-08-04 ユーロ−セルティーク，エス．エイ． アリールチオキサンチン類
US6248746B1 (en) * 1998-01-07 2001-06-19 Euro-Celtique S.A. 3-(arylalkyl) xanthines
JP2002516315A (ja) * 1998-05-26 2002-06-04 ナチュラル ドラッグ サイエンシズ，リミティド ライアビリティ カンパニー ５−オキシミノバルビツール酸のｎ−置換誘導体
WO2001029010A1 (en) * 1999-10-21 2001-04-26 Merck & Co., Inc. Gram-positive selective antibacterial compounds, compositions containing such compounds and methods of treatment
GB0008694D0 (en) * 2000-04-07 2000-05-31 Novartis Ag Organic compounds
US20080194593A1 (en) 2001-11-09 2008-08-14 Rao Kalla A2b adenosine receptor antagonists
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
ZA200607252B (en) * 2004-03-15 2008-05-28 Takeda Pharmaceutical Dipeptidyl peptidase inhibitors
CN102079743B (zh) * 2004-03-15 2020-08-25 武田药品工业株式会社 二肽基肽酶抑制剂
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
KR100883289B1 (ko) * 2004-06-11 2009-02-11 니뽄 다바코 산교 가부시키가이샤 암 치료용5-아미노-2,4,7-트리옥소-3,4,7,8-테트라히드로-2ｈ-피리도[2,3-ｄ]피리미딘 유도체 및 관련 화합물
AU2006229791A1 (en) * 2005-03-24 2006-10-05 Janssen Pharmaceutica, N.V. Pyrimidindione derivatives as prokineticin 2 receptor antagonists
TW200745079A (en) 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
WO2007035629A2 (en) 2005-09-16 2007-03-29 Takeda Pharmaceutical Company Limited Process for the preparation of pyrimidinedione derivatives
TW200745080A (en) 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
GB0605785D0 (en) * 2006-03-22 2006-05-03 Glaxo Group Ltd Compounds
TWI394747B (zh) * 2006-06-23 2013-05-01 Smithkline Beecham Corp 脯胺醯基羥化酶抑制劑
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
AR067557A1 (es) 2007-07-19 2009-10-14 Takeda Pharmaceutical Preparacion solida y metodo de preparacion
CA2749893A1 (en) 2009-02-04 2010-08-12 Pfizer Inc. 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one derivatives

Also Published As

Publication number Publication date
CA2755561A1 (en) 2010-09-30
MX2011010079A (es) 2011-10-10
US20120029000A1 (en) 2012-02-02
EP2410855A1 (en) 2012-02-01
BRPI1013561A2 (pt) 2015-08-25
JP2012521411A (ja) 2012-09-13
EP2410855A4 (en) 2012-10-17
BRPI1013561A8 (pt) 2015-09-22
CN102361557A (zh) 2012-02-22
EP2410855B1 (en) 2016-06-01
US8841447B2 (en) 2014-09-23
WO2010109468A1 (en) 2010-09-30

Similar Documents

Publication Publication Date Title
EP2410855B1 (en) Process for the preparation of alogliptin
KR101368988B1 (ko) 디펩티딜 펩티다제 억제제
KR100819668B1 (ko) 신규한 피리미딘-설퍼아마이드
US8114866B2 (en) Derivatives of 1-piperazine- and 1-homopiperazine-carboxylates, preparation method thereof and use of same as inhibitors of the FAAH enzyme
CA3034010A1 (en) Amino-pyrrolopyrimidinone compounds and methods of use thereof
US10662187B2 (en) Bruton's tyrosine kinase inhibitors
EP2864318B1 (en) 2-aminopyrazine derivatives as csf-1r kinase inhibitors
CA2736281C (en) Tri-substituted pyrimidine compounds and their use as pde10 inhibitors
EP2909189B1 (en) Heteroaryl linked quinolinyl modulators of ror-gamma-t
KR20150092279A (ko) 암의 치료를 위한 신규한 2-고리 페닐-피리딘/피라진
EP3368529A1 (en) Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
WO2008116742A1 (en) Aza-pyridopyrimidinone derivatives
CN111377873B (zh) 氨基嘧啶化合物及其制备方法和用途
AU2003285321B2 (en) Pyrimidine-sulfamides and their use as endothelian receptor antagonist
WO2009085797A1 (en) Processes for preparing hiv reverse transcriptase inhibitors
EP1309564B1 (en) Arylethene-sulfonamides, their preparation and their use as endothelin antagonists
EP0768311B1 (en) Pyrrolocarbazole derivatives
AU2022475622B2 (en) 5-pyridine-1h-indazole compound, pharmaceutical composition, and use
US6337334B1 (en) Pyrimidine derivatives
JP2011111433A (ja) ウレイド構造を有するウラシル化合物又はその塩
CA2554705A1 (en) Alpha-4 integrin mediated cell adhesion inhibitors for the treatment or prevention of inflammatory diseases
WO2019005297A1 (en) BACE1 INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
US10793566B2 (en) Bruton's tyrosine kinase inhibitors
US20230094404A1 (en) Method for preparation of heterocyclicamine derivatives
HK1165216A (en) Process for the preparation of alogliptin

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application